Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Non-linear increases in danazol exposure with dose in older vs. younger beagle dogs: the potential role of differences in bile salt concentration, thermodynamic activity, and formulation digestion.

Anby MU, Williams HD, Feeney O, Edwards GA, Benameur H, Pouton CW, Porter CJ.

Pharm Res. 2014 Jun;31(6):1536-52. doi: 10.1007/s11095-013-1260-8. Epub 2014 Jan 30.

PMID:
24477676
2.

An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulations.

Anby MU, Nguyen TH, Yeap YY, Feeney OM, Williams HD, Benameur H, Pouton CW, Porter CJ.

Mol Pharm. 2014 Nov 3;11(11):4069-83. doi: 10.1021/mp500197b. Epub 2014 Sep 29.

PMID:
25265395
3.
4.
5.

'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.

Feeney OM, Williams HD, Pouton CW, Porter CJ.

J Control Release. 2014 Oct 28;192:219-27. doi: 10.1016/j.jconrel.2014.07.037. Epub 2014 Jul 22.

PMID:
25058571
6.

Relative bioavailability of danazol in dogs from liquid-filled hard gelatin capsules.

Erlich L, Yu D, Pallister DA, Levinson RS, Gole DG, Wilkinson PA, Erlich RE, Reeve LE, Viegas TX.

Int J Pharm. 1999 Mar 1;179(1):49-53.

PMID:
10053201
7.

Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion.

Williams HD, Anby MU, Sassene P, Kleberg K, Bakala-N'Goma JC, Calderone M, Jannin V, Igonin A, Partheil A, Marchaud D, Jule E, Vertommen J, Maio M, Blundell R, Benameur H, Carrière F, Müllertz A, Pouton CW, Porter CJ.

Mol Pharm. 2012 Nov 5;9(11):3286-300. doi: 10.1021/mp300331z. Epub 2012 Oct 22.

PMID:
23030411
8.

Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs.

Cuiné JF, McEvoy CL, Charman WN, Pouton CW, Edwards GA, Benameur H, Porter CJ.

J Pharm Sci. 2008 Feb;97(2):995-1012.

PMID:
18064698
9.
10.

Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis.

Larsen A, Holm R, Pedersen ML, Müllertz A.

Pharm Res. 2008 Dec;25(12):2769-77. doi: 10.1007/s11095-008-9641-0. Epub 2008 Jul 1.

PMID:
18592356
11.

In vitro and ex vivo investigation of the impact of luminal lipid phases on passive permeability of lipophilic small molecules using PAMPA.

Markopoulos C, Imanidis G, Vertzoni M, Symillides M, Parrott N, Reppas C.

Pharm Res. 2013 Dec;30(12):3145-53. doi: 10.1007/s11095-013-1141-1. Epub 2013 Jul 27.

PMID:
23893021
12.

Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation.

Yeap YY, Trevaskis NL, Quach T, Tso P, Charman WN, Porter CJ.

Mol Pharm. 2013 May 6;10(5):1874-89. doi: 10.1021/mp3006566. Epub 2013 Mar 27.

PMID:
23480483
13.

A simplified method to screen for in-vivo performance of oral lipid formulations.

Kilic M, Dressman J.

J Pharm Pharmacol. 2014 May;66(5):615-23. doi: 10.1111/jphp.12182. Epub 2013 Dec 3.

PMID:
24313318
14.

A dynamic in vitro lipolysis model. II: Evaluation of the model.

Zangenberg NH, Müllertz A, Kristensen HG, Hovgaard L.

Eur J Pharm Sci. 2001 Oct;14(3):237-44.

PMID:
11576829
15.

The potential for drug supersaturation during intestinal processing of lipid-based formulations may be enhanced for basic drugs.

Yeap YY, Trevaskis NL, Porter CJ.

Mol Pharm. 2013 Jul 1;10(7):2601-15. doi: 10.1021/mp400035z. Epub 2013 Jun 10.

PMID:
23697606
16.
17.

Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems.

Anby MU, Williams HD, McIntosh M, Benameur H, Edwards GA, Pouton CW, Porter CJ.

Mol Pharm. 2012 Jul 2;9(7):2063-79. doi: 10.1021/mp300164u. Epub 2012 Jun 15.

PMID:
22656917
18.

Formulation of a danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability.

Childs SL, Kandi P, Lingireddy SR.

Mol Pharm. 2013 Aug 5;10(8):3112-27. doi: 10.1021/mp400176y. Epub 2013 Jul 18.

20.

Single oral dose pharmacokinetics and comparative bioavailability of danazol in humans.

Hooper WD, Eadie MJ, Dickinson RG.

Biopharm Drug Dispos. 1991 Nov;12(8):577-82.

PMID:
1801964

Supplemental Content

Support Center